Navigation Links
Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team
Date:7/19/2013

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. 

Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research Team. 

"We are excited to have Marshall join our team. He has had a distinguished career on Wall Street, and this experience coupled with his deep analytical skills make him an excellent addition to Royalty Pharma," said Pablo Legorreta, Founder and CEO of Royalty Pharma.

Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $10 billion in assets, Royalty Pharma owns royalty interests in 41 marketed and late stage biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's Cimzia®, Biogen Idec's Tecifidera® and Pharmacyclics' ibrutinib. Additional company information is available at royaltypharma.com.

Royalty Pharma | RP Management LLC
Investor Relations
+ 1 (212) 883-0200
ir@royaltypharma.com


'/>"/>
SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cowen Healthcare Royalty Partners Raises $1 Billion
2. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
3. Royalty Pharma Statement Regarding Elan Proposal
4. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
5. Royalty Pharma Statement Regarding Elan Law Suits
6. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
7. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Pharmasset Reports Fiscal Year End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
(Date:2/23/2017)... Wisconsin (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses ... with reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency ...
(Date:2/23/2017)... -- Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, parks and ... lice treatment salon to set up shop. But there,s ... French bistro on E Madison Ave, and CEO Maria ... lice clinic, we pride ourselves on being a destination for ... the stigma associated with lice. Everyone can get lice – ...
(Date:2/23/2017)... ... February 23, 2017 , ... David Nolte, PhD accepted Purdue ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization ... to, and success with, commercializing discoveries from Purdue research. “This award is truly ...
Breaking Biology Technology:
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
(Date:1/30/2017)... 30, 2017   Invitae Corporation (NYSE: ... information companies, today announced that it will report its ... 2017 guidance on Monday, February 13, 2017, and Invitae,s ... at 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... briefly review financial results, guidance, and recent developments and ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
Breaking Biology News(10 mins):